A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer

Cancer Chemotherapy and Pharmacology

Volumn 65, Issue 1, 2009, Pages 113-120

  Furuse, Junji ^a,j   Okusaka, Takuji ^b   Ohkawa, Shinichi ^c   Nagase, Michitaka ^d   Funakoshi, Akihiro ^e   Boku, Narikazu ^f   Yamao, Kenji ^g   Yamaguchi, Taketo ^h   Sato, Toshiya ⁱ  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c KANAGAWA CANCER CENTER   (Japan)

^d TOCHIGI CANCER CENTER   (Japan)

^e NATIONAL KYUSHU CANCER CENTER   (Japan)

^f SHIZUOKA CANCER CENTER   (Japan)

^g AICHI CANCER CENTER HOSPITAL   (Japan)

^h CHIBA UNIVERSITY   (Japan)

ⁱ KYOTO UNIVERSITY SCHOOL OF PUBLIC HEALTH   (Japan)

^j KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Biliary tract cancer; Doxorubicin; Phase II study; Prognostic factor; Systemic chemotherapy; Uracil tegafur

Indexed keywords

DOXORUBICIN; GEMCITABINE; LACTATE DEHYDROGENASE; UFT;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; AMPULLARY CANCER; ANEMIA; ANOREXIA; ARTICLE; BILIARY TRACT CANCER; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DEPIGMENTATION; DIARRHEA; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDEMA; EXTRAHEPATIC CHOLANGIOCARCIOMA; FATIGUE; FEMALE; GALLBLADDER CANCER; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HUMAN; INTRAHEPATIC CHOLANGIOCARCINOMA; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SORE THROAT; SURVIVAL TIME; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

AGED; AMPULLA OF VATER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BILIARY TRACT NEOPLASMS; CHOLANGIOCARCINOMA; COMMON BILE DUCT NEOPLASMS; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; GALLBLADDER NEOPLASMS; HUMANS; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TEGAFUR; TREATMENT OUTCOME; URACIL;

EID: 70349616325     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1011-z     Document Type: Article

References (30)

1. Sobin LH, Wittekind CH (eds) (2002) TNM classification of malignant tumours. Liver, UICC, 6th edn. Wiley-Liss, New York, pp 82-83
2. National Cancer Center. Cancer statistics in Japan 2007. http://www.fpcr.or.jp/publication/statistics.html. Accessed 10 March, 2008
3. B Glimelius K Hoffman PO Sjoden, et al. 1996 Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer Ann Oncol 7 593 600 8879373 1:STN:280:DyaK2s%2FjtlOitw%3D%3D
4. M Hejna M Pruckmayer M Raderer 1998 The role of chemotherapy and radiation in the management of biliary cancer: a review of the literature Eur J Cancer 34 977 986 9849443 10.1016/S0959-8049(97)10166-6 1:CAS:528: DyaK1cXks1Gmsb0%3D (Pubitemid 28308335)
5. G Falkson JM MacIntyre CG Moertel 1984 Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer Cancer 54 965 969 6235908 10.1002/1097-0142(19840915)54:6<965::AID- CNCR2820540603>3.0.CO;2-X 1:STN:280:DyaL2c3ot1ahtA%3D%3D
6. YZ Patt DV Jones Jr A Hoque R Lozano A Markowitz I Raijman, et al. 1996 Phase II trial of intravenous fluorouracil and subcutaneous interferon alpha-2b for biliary tract cancer J Clin Oncol 14 2311 2315 8708722 1:CAS:528: DyaK28XltFSqsbg%3D
7. JH Harvey FP Smith PS Schein 1984 5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract J Clin Oncol 2 1245 1248 6092556 1:STN:280:DyaL2M%2Fjt1yjtg%3D%3D
8. PA Ellis A Norman A Hill, et al. 1995 Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours Eur J Cancer 31A 1594 1598 7488407 10.1016/0959-8049(95)00323-B 1:CAS:528:DyaK2MXpsl2rs7o%3D
9. C Morizane S Okada T Okusaka H Ueno T Saisho 2003 Phase II study of cisplatin, epirubicin, and continuous-infusion 5-fluorouracil for advanced biliary tract cancer Oncology 64 475 476 12759549 10.1159/000070310 (Pubitemid 36682965)
10. S Rao D Cunningham RE Hawkins, et al. 2005 Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer Br J Cancer 92 1650 1654 15856037 10.1038/sj.bjc.6602576 1:CAS:528:DC%2BD2MXjvVantrs%3D (Pubitemid 40756474)
11. M Penz GV Kornek M Raderer, et al. 2001 Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer Ann Oncol 12 183 186 11300321 10.1023/A:1008352123009 1:STN:280:DC%2BD3M3gvFansg%3D%3D (Pubitemid 32223865)
12. N Tsavaris C Kosmas P Gouveris, et al. 2004 Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer Invest New Drugs 22 193 198 14739669 10.1023/B:DRUG.0000011797.09549.53 1:CAS:528:DC%2BD2cXisleiug%3D%3D (Pubitemid 38270476)
13. T Okusaka H Ishii A Funakoshi, et al. 2006 Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer Cancer Chemother Pharmacol 57 647 653 16142487 10.1007/s00280-005-0095-3 1:CAS:528: DC%2BD28XhsVartLY%3D (Pubitemid 43237850)
14. C Hsu YC Shen CH Yang, et al. 2004 Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract Br J Cancer 90 1715 1719 15150619 1:CAS:528:DC%2BD2cXkvFWlur4%3D
15. SR Alberts H Al-Khatib MR Mahoney, et al. 2005 Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial Cancer 103 111 118 15558814 10.1002/cncr.20753 1:CAS:528:DC%2BD2MXmtVarsA%3D%3D (Pubitemid 39665463)
16. JJ Knox D Hedley A Oza, et al. 2005 Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial J Clin Oncol 23 2332 2338 15800324 10.1200/JCO.2005.51.008 1:CAS:528: DC%2BD2MXjsVyhsr0%3D (Pubitemid 46218726)
17. JY Cho YH Paik YS Chang, et al. 2005 Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma Cancer 104 2753 2758 16294346 10.1002/cncr.21591 1:CAS:528:DC%2BD28XptlSktQ%3D%3D (Pubitemid 41798285)
18. DC Doval JS Sekhon SK Gupta, et al. 2004 A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer Br J Cancer 90 1516 1520 15083178 10.1038/sj.bjc.6601736 1:CAS:528: DC%2BD2cXjtVWktL4%3D (Pubitemid 38648231)
19. S Thongprasert S Napapan C Charoentum, et al. 2005 Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma Ann Oncol 16 279 281 15668284 10.1093/annonc/mdi046 1:STN:280:DC%2BD2M%2FjvFyhsw%3D%3D (Pubitemid 40309310)
20. T Andre C Tournigand O Rosmorduc, et al. 2004 Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study Ann Oncol 15 1339 1343 15319238 10.1093/annonc/mdh351 1:STN:280: DC%2BD2cvhsVektg%3D%3D (Pubitemid 39295020)
21. R Kuhn A Hribaschek K Eichelmann, et al. 2002 Outpatient therapy with gemcitabine and docetaxel for gallbladder, biliary, and cholangio-carcinomas Invest New Drugs 20 351 356 12201499 10.1023/A:1016209901417 1:CAS:528:DC%2BD38XltFansrY%3D (Pubitemid 34823765)
22. RR McWilliams NR Foster FJ Quevedo, et al. 2007 NCCTG phase I/II trial (N9943) of gemcitabine and pemetrexed in patients with biliary tract or gallbladder carcinoma: phase II results J Clin Oncol, Proc Am Soc Clin Oncol 25 217s (abstr 4578)
23. S Fujii K Ikenaka M Fukushima T Shirasaka 1978 Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5- fluorouracil Jpn J Cancer Res (Gann) 69 763 772
24. R Pazdur Y Lassere E Diaz-Canton B Bready DH Ho 1996 Phase I trials of uracil-tegafur (UFT) using 5 and 28 day administration schedules: demonstration of schedule-dependent toxicities Anticancer Drugs 7 728 733 8949982 10.1097/00001813-199609000-00002 1:CAS:528:DyaK28XntFyqsr0%3D
25. J Furuse T Okusaka A Funakoshi K Yamao M Nagase H Ishii, et al. 2006 Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer Jpn J Clin Oncol 36 552 556 16887837 10.1093/jjco/hyl075 (Pubitemid 44593897)
26. J Furuse T Okusaka N Boku S Ohkawa A Sawaki T Masumoto A Funakoshi 2008 S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study Cancer Chemother Pharmacol 62 5 849 855 18214482 10.1007/s00280-007-0673-7 1:CAS:528:DC%2BD1cXht1CjtLvP
27. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
28. F Eckel RM Schmid 2007 Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials Br J Cancer 96 896 902 17325704 10.1038/sj.bjc.6603648 1:CAS:528:DC%2BD2sXjt1SrsLw%3D (Pubitemid 46452283)
29. J Furuse T Takada M Miyazaki, et al. 2008 Guidelines for chemotherapy of biliary tract and ampullary carcinomas J Hepatobiliary Pancreat Surg 15 55 62 18274844 10.1007/s00534-007-1280-z (Pubitemid 351279841)
30. N Yonemoto J Furuse T Okusaka K Yamao A Funakoshi S Ohkawa N Boku K Tanaka M Nagase H Saisho T Sato 2007 A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer Jpn J Clin Oncol 37 843 851 17942578 10.1093/jjco/hym116 (Pubitemid 350259003)